In the Original Investigation titled “Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial,”1 an incorrect analysis of the mean deviations for visual field loss over time led to errors in eTable 6 in Supplement 3. These errors did not affect the conclusions of the article. A Letter of Explanation2 has been published that details the source of these errors. This article has been corrected online.
References
- 1.Gross JG, Glassman AR, Liu D, et al. ; Diabetic Retinopathy Clinical Research Network . Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018;136(10):1138-1148. doi: 10.1001/jamaophthalmol.2018.3255 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Glassman AR. Incorrect data in supplement [published online February 28, 2019]. JAMA Ophthalmol. doi: 10.1001/jamaophthalmol.2019.0001 [DOI] [PubMed] [Google Scholar]